Xaluprine (previously Mercaptopurine Nova Laboratories)

RSS

mercaptopurine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.

This EPAR was last updated on 08/05/2019

Authorisation details

Product details
Name
Xaluprine (previously Mercaptopurine Nova Laboratories)
Agency product number
EMEA/H/C/002022
Active substance
6-mercaptopurine monohydrate
International non-proprietary name (INN) or common name
mercaptopurine
Therapeutic area (MeSH)
Leukemia, Lymphoid
Anatomical therapeutic chemical (ATC) code
L01BB02
OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Nova Laboratories Ireland Limited
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
09/03/2012
Contact address

3rd Floor, Ulysses House
Foley Street
Dublin 1, D01 W2T2
Ireland

Product information

24/04/2019 Xaluprine (previously Mercaptopurine Nova Laboratories) - EMEA/H/C/002022 - IAIN/0021/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

Assessment history

How useful was this page?

Add your rating
Average
1 rating